Evidence map›Paper›PMID 29076032›Full record

ArticleAIDS and behavior2018

Brief Participant-Centered Convergence Interviews Integrate Self-Reports, Product Returns, and Pharmacokinetic Results to Improve Adherence Measurement in MTN-017.

Iván C Balán, Rebecca Giguere, William Brown, Alex Carballo-Diéguez, Stephanie Horn, Craig W Hendrix, Mark A Marzinke, Ratiya Pamela Kunjara Na Ayudhya, Karen Patterson, Jeanna M Piper and 4 more

Registry-linked trialAbstract read
In one paragraph

Article in AIDS and behavior, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01687218 (A Phase 2 Randomized Sequence Open Label Expanded Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel), which is not on this map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01687218 phase2completednot on this map

A Phase 2 Randomized Sequence Open Label Expanded Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel

TypeinterventionalSponsorCONRADRan2013 to 2015Enrolled195ConditionsHIVArmsOral FTC/TDF (Daily Emtricitabine/Tenofovir Disoproxil fumarate Tablet), Rectal Daily TFV RG 1% gel (Rectally applied Tenofovir Reduced Glycerin 1% Gel), Rectal RAI-associated TFV RG 1% gel (Receptive Anal Intercourse Associated rectally applied Tenofovir Reduced Glycerin 1% Gel)
3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Iván C BalánHIV Center for Clinical and Behavioral Studies at New York State Psychiatric Institute and Columbia University, Unit 15, 1051 Riverside Drive, New York, NY, 10032, USA. balaniv@nyspi.columbia.edu.
Rebecca GiguereHIV Center for Clinical and Behavioral Studies at New York State Psychiatric Institute and Columbia University, Unit 15, 1051 Riverside Drive, New York, NY, 10032, USA.
William BrownDepartment of Medicine, Center for AIDS Prevention Studies, University of California San Francisco, San Francisco, CA, USA.
Alex Carballo-DiéguezHIV Center for Clinical and Behavioral Studies at New York State Psychiatric Institute and Columbia University, Unit 15, 1051 Riverside Drive, New York, NY, 10032, USA.
Stephanie HornFHI 360, Durham, NC, USA.
Craig W HendrixDepartment of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Mark A MarzinkeDepartment of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Ratiya Pamela Kunjara Na AyudhyaMagee-Womens Research Institute, Pittsburgh, PA, USA.
Karen PattersonStatistical Center for HIV/AIDS Research & Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Jeanna M PiperDivision of AIDS, National Institute of Allergy and Infectious Diseases, Rockville, MD, USA.
Ian McGowanSchool of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Javier R LamaAsociación Civil Impacta Salud y Educación, Lima, Peru.
Ross D CranstonSchool of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
MTN-017 Protocol Team

Funding

Microbicide Trials NetworkUM1AI068633 · NIAID · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI HILLIER, SHARON L. · 2011 to 2021
$175.0M
Microbicide Trials NetworkU01AI068633 · NIAID · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI HILLIER, SHARON L. · 2006 to 2010
$77.0M
Statistical and Data Management Center (SDMC): Microbicide Trials NetworkUM1AI068615 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BROWN, ELIZABETH RENATA · 2011 to 2021
$66.5M
Ujima Mentoring ProgramP30MH062246 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MALLORY O JOHNSON · 2001 to 2026
$57.4M
The Statistics, Data Science, and Data Management (SDM) CoreP30MH043520 · NIMH · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI Claude Ann Mellins · 2003 to 2026
$48.2M
University of Pittsburgh Clinical Trials UnitUM1AI069494 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SUSAN L KOLETAR, John W Mellors · 2012 to 2026
$38.0M
Laboratory Center (LC): Microbicide Trials NetworkUM1AI106707 · NIAID · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI MELLORS, JOHN W, ROHAN, LISA CENCIA · 2014 to 2021
$27.1M
Leadership for HIV/AIDS Clinical Trials Networks; Microbicide Trials NetworkU01AI068615 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI RICHARDSON, BARBRA A · 2006 to 2010
$20.4M
SEXUAL RISK BEHAVIOR AND BEHAVIOR CHANGE IN HETEROSEXUAL WOMEN AND MENP50MH043520 · NIMH · NEW YORK STATE PSYCHIATRIC INSTITUTE · PI WARNE, PATRICIA A · 1987 to 2002
$5.0M
The Next Frontier in Diabetes Communication: Promoting Health Literacy in the Era of Secure MessagingR01LM012355 · NLM · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KARTER, ANDREW JOHN, SCHILLINGER, DEAN · 2015 to 2018
$2.8M
NIAID NIH HHS UM1 AI068615NIAID NIH HHS UM1 AI068633NIAID NIH HHS UM1 AI069494NIAID NIH HHS UM1 AI106707NIMH NIH HHS P30 MH043520NIMH NIH HHS P30 MH062246NLM NIH HHS R01 LM012355
6 · The paper itself

Abstract

MTN-017 compared the safety and acceptability of daily oral emtricitabine/tenofovir disoproxil fumarate, daily reduced-glycerin 1% tenofovir gel applied rectally, and the same gel applied before and after receptive anal intercourse. The Data Convergence Interview (DCI) and the Pharmacokinetic Data Convergence Interview (PK-DCI) were brief, collaborative interactions conducted with participants during adherence counseling sessions to improve accurate measurement of adherence to study product use. DCIs converged data from product return counts and participants' responses to daily text messages. PK-DCIs, conducted 4 weeks later, converged results of the DCI with PK from the corresponding period. CIs were easily incorporated into adherence counseling sessions, increased the accuracy of adherence data, and provided valuable context to data on product use. Participants were readily engaged in the interviews but, if they felt confronted, provided more guarded responses. As such, how these CIs are conducted is critical to engage participants, even those with poor adherence, to openly discuss challenges with product use.

Indexed as

CounselingDrug MonitoringAdultAnti-HIV AgentsData AccuracyEmtricitabineFemaleHIV InfectionsHumansMaleSelf ReportTenofovirAnti-HIV AgentsEmtricitabineTenofovirAdherenceBiomarkerClient-centered counselingData accuracy

Identifiers

PMID29076032
PMCPMC5983888

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.